A MULTI-CENTER, RANDOMIZED, OPEN-LABEL, NONINFERIORITY TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE, ORAL DOSE OF ZOLIFLODACIN COMPARED TO A COMBINATION OF A SINGLE INTRAMUSCULAR DOSE OFCEFTRIAXONE AND A SINGLE ORAL DOSE OF AZITHROMYCIN IN THE TREATMENT OF PATIENTS WITH UNCOMPLICATED GONORRHOEA
T
Teresa Batteiger, MD
Primary Investigator
Administratively Closed
18 years - 100 years
All
Phase
3
1 Location
Brief description of study
To assess the efficacy of a single, oral, 3 grams (g) dose of zoliflodacin compared to a combination of a single intramuscular (IM) 500 milligram (mg) dose of ceftriaxone and a single 1 g oral dose of azithromycin for the treatment of uncomplicated urogenital gonorrhoea
Detailed description of study
Adults 18 years of age and older are needed for a study assessing gonorrhea treatment. This study is being conducted by Dr. Teresa Batteiger at Indiana University School of Medicine and takes place in the Bell Flower Clinic of the Fifth Third Office Building, next to Eskenazi Hospital.
This study will compare medication that is normally offered versus a new study medication for treatment of gonorrhea in individuals with or without HIV infection.
Gonorrhea treatment provided
HIV treatment NOT provided
3 clinic visits and 1 phone visit over 30 days
Willing to get an HIV test
Payment given for participation in the study
Risks disclosed before participation
HIV treatment NOT provided
3 clinic visits and 1 phone visit over 30 days
Willing to get an HIV test
Payment given for participation in the study
Risks disclosed before participation
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: teens,teenager,teenagers,adolescent,adolescents,adult,adults,gonorrhea
-
Age: 18 years - 100 years
-
Gender: All
Additional Information:
For information or to see if you qualify, call Lora at 317-274-8453
Updated on
15 May 2025.
Study ID: 1905015597
